Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 83,857 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Phase 1 Interventional

GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

NCT03576612
View directory record Official record
Conditions
Glioma, Malignant
Interventions
AdV-tk, Valacyclovir, Radiation, Temozolomide, Nivolumab, Laboratory Biomarker Analysis
Biological · Drug · Radiation + 1 more
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 23, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

NCT01865812
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 23, 2026, 9:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

NCT02401542
View directory record Official record
Conditions
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
Interventions
Vofatamab, Docetaxel, Placebo
Drug
Lead sponsor
Rainier Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Gilbert, Arizona • Goodyear, Arizona • Duarte, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 23, 2026, 9:20 PM EDT
Not yet recruiting Phase 4 Interventional

Outcomes of CTAK Surgery

NCT07474870
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Questionnaire and Physical Exam
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 9:20 PM EDT
Terminated Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00087373
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
recombinant fowlpox-TRICOM vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 23, 2026, 9:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users

NCT01596673
View directory record Official record
Conditions
Drug Abuse
Interventions
45-mg hydrocodone bitartrate extended-release tablet (crushed or intact), Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 23, 2026, 9:20 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma

NCT00992173
View directory record Official record
Conditions
Neuroblastoma
Interventions
Ultratrace Iobenguane I 131
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 23, 2026, 9:20 PM EDT
Enrolling by invitation Not applicable Interventional

Substance Use and HIV Action for Reentry and Engagement.

NCT06810973
View directory record Official record
Conditions
HIV
Interventions
SUCCESS-E, Enhanced Standard of Care, Key Informant Interviews
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 23, 2026, 9:20 PM EDT
Recruiting Phase 2 Interventional

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

NCT05847569
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

NCT04452669
View directory record Official record
Conditions
COVID-19
Interventions
VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
Drug
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 23, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

NCT03231969
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%, Bilastine 0%
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 23, 2026, 9:20 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

NCT05855369
View directory record Official record
Conditions
Smell Dysfunction, Olfactory Disorder, Long COVID
Interventions
Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO)
Device · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 23, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

NCT05628883
View directory record Official record
Conditions
Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, Ocular Melanoma, Uveal Melanoma, Iris Melanoma, Conjunctival Melanoma, Non-Cutaneous Melanoma
Interventions
TBio-4101, Cyclophosphamide, Fludarabine, Interleukin-2
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 23, 2026, 9:20 PM EDT
Recruiting Phase 2 Interventional

ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer

NCT07425054
View directory record Official record
Conditions
Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus
Interventions
HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab
Radiation · Drug
Lead sponsor
Jennifer Dorth
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 9:20 PM EDT
Completed Not applicable Interventional

fMRI Study of Expectancy on Acupuncture Treatment Outcomes in Knee OA

NCT01040754
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Acupuncture
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 23, 2026, 9:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Suppression of Toll Like Receptors by Insulin

NCT01151605
View directory record Official record
Conditions
Insulin Resistance
Interventions
insulin infusion, Dextrose infusion, Saline Infusion
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
20 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 9:20 PM EDT
Completed Phase 2Phase 3 Interventional

Cyrotherapy vs. APC in GAVE

NCT00587405
View directory record Official record
Conditions
Watermelon Stomach
Interventions
cryotherapy, Argon Plasma Coagulation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 23, 2026, 9:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Social Functioning in Opioid Use Disorder

NCT07044466
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
CBT4CBT-Buprenorphine
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 9:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

NCT01332266
View directory record Official record
Conditions
Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Interventions
E7050, Cetuximab
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
7
States / cities
Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 23, 2026, 9:20 PM EDT
Withdrawn Phase 1 Interventional

Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)

NCT00800566
View directory record Official record
Conditions
Leukemia, Chronic Lymphocytic Leukemia
Interventions
Oral Clofarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 23, 2026, 9:20 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

NCT02937766
View directory record Official record
Conditions
Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 23, 2026, 9:20 PM EDT
Completed Not applicable Interventional

Non-Invasive Imaging for Cording in Breast Cancer Patients

NCT01427166
View directory record Official record
Conditions
Breast Cancer
Interventions
Non invasive venous ultrasound
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 23, 2026, 9:20 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

NCT00609622
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
sunitinib, mFOLFOX6, bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
81
States / cities
Fairhope, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 23, 2026, 9:20 PM EDT
Recruiting Phase 3 Interventional

Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos

NCT06746129
View directory record Official record
Conditions
Infertility (IVF Patients)
Interventions
embryo transfer
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 23, 2026, 9:20 PM EDT